Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Equity Average (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Equity Average for 6 consecutive years, with $1.2 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Equity Average fell 98.44% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Sep 2019, down 98.44%, and an annual FY2018 reading of $40.6 million, down 59.42% over the prior year.
  • Equity Average was $1.2 million for Q3 2019 at Larimar Therapeutics, up from $883500.0 in the prior quarter.
  • Across five years, Equity Average topped out at $213.9 million in Q2 2015 and bottomed at $883500.0 in Q2 2019.
  • Average Equity Average over 5 years is $104.8 million, with a median of $105.2 million recorded in 2017.
  • The sharpest move saw Equity Average skyrocketed 67.32% in 2015, then tumbled 98.49% in 2019.
  • Year by year, Equity Average stood at $179.4 million in 2015, then decreased by 29.8% to $126.0 million in 2016, then plummeted by 33.53% to $83.7 million in 2017, then plummeted by 36.19% to $53.4 million in 2018, then crashed by 97.72% to $1.2 million in 2019.
  • Business Quant data shows Equity Average for LRMR at $1.2 million in Q3 2019, $883500.0 in Q2 2019, and $2.1 million in Q1 2019.